Revista de síndrome metabólico

Use of Lorcaserin, A 5HT2C Agonist, In the Management of OlanzapineInduced Weight Gain

Abstract

Charles Nguyen , Amanda Suzuki and Kevin Bera

Atypical antipsychotics are associated with weight gain, which compromise medication adherence and pose longterm health complications. These are two cases in which lorcaserin, a 5HT2C agonist, has been used to counteract olanzapine-induced weight gain in conjunction with a low carbohydrate diet. In Case 1, patient lost a significant amount of weight and reported decreased food cravings. In Case 2, patient showed initial response but was unable to maintain diet. Patient had significant weight gain and reported increased cravings after discontinuing lorcaserin. These cases demonstrate 5HT2C agonists’ potential for management of atypical antipsychotic-related weight gain.